{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-168448","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.175146+00:00","generated_at":"2026-06-13T22:35:12.018393+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Coherus to acquire Surface Oncology for upfront stock worth ~$40M+ net cash plus CVRs","bullets":["Upfront consideration: Coherus stock valued using $5.2831/share based on $40M plus Surface's net cash (min $19.6M).","Each Surface share also receives one CVR for 70% of milestones/royalties from GSK and Novartis partnerships.","CVRs also include 25% of upfront payments for SRF114 and 50% for SRF388 out-licensing, less development costs.","Closing conditions: Surface stockholder approval, net cash ≥$19.6M, S-4 effectiveness, and no material adverse effect.","Termination fee of ~$2M payable by Surface if it accepts a superior proposal or breaches non-solicitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-168448","json":"https://secwatch.observer/filing/0001193125-23-168448.json","markdown":"https://secwatch.observer/filing/0001193125-23-168448.md","text":"https://secwatch.observer/filing/0001193125-23-168448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000119312523168448/0001193125-23-168448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000119312523168448/d523169d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:35:12.018393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c341301bc068fdd65f592b32d7284c8b98c1a585","claim":"Coherus Oncology, Inc. entered into Agreement and Plan of Merger with Surface Oncology, Inc. (effective 2023-06-15).","evidence_excerpt":"On June 15, 2023, Coherus BioSciences, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Crimson Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub I ”), Crimson Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“ Merger Sub II ” and together with Merger Sub I, the “ Merger Subs ”), and Surface Oncology, Inc., a Delaware corporation (“ Surface ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000119312523168448/0001193125-23-168448-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Surface Oncology, Inc."},{"label":"Effective","value":"2023-06-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}